Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06069284
Other study ID # ILBS-ACLF-12
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 25, 2023
Est. completion date September 30, 2024

Study information

Verified date September 2023
Source Institute of Liver and Biliary Sciences, India
Contact Dr Sudhir Kumar, MD
Phone 01146300000
Email sudhirkgmu@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute-on-chronic liver failure (ACLF) is a syndrome associated with a high short- term mortality. Early identification of patients at high risk is important to determine emergency for transplantation and prioritize the need for intensive care unit. Unbalanced systemic inflammatory response is closely associated with mortality in ACLF patients. This systemic inflammatory response in ACLF increases liver and splenic stiffness stiffnes, which can be detected by transient elastography. Very few studies have been done in past evaluating liver and splenic stiffness as prognostic tool in patients of ACLF. These studies have taken only single value of liver and splenic stiffness as prognostic tool. No follow up study have yet been done assessing acute change in liver and splenic stiffness in ACLF. In this study, we hypothesize that acute change in liver and splenic stiffness at 7th & 14 th day predicts outcome in ACLF patients. With this study, we aim to evaluate whether acute changes in liver and splenic stiffness at 7th & 14th day predicts outcome at 3 months in patients of ACLF.


Description:

Study Design 1 year prospective cohort study Hypothesis: We hypothesize that acute change in liver and splenic stiffness at 7th & 14 th day predicts outcome in ACLF patients Aim and Objective - Primary objective: To study the change in liver and splenic stiffness values at day 7 from baseline at day 1 between those with or without transplant free survival at Day 90. Secondary objectives: 1) To study the change in liver and splenic stiffness values at day 14 from baseline at day 1 between those with or without transplant free survival at Day 90. 1. To evaluate association of baseline and change in liver and splenic stiffness with different etiologies of ACLF 2. To evaluate association of baseline liver and splenic stiffness with grade of esophageal varices in ACLF patients. 3. To evaluate association of baseline and change in liver and splenic stiffness with pattern of organ failures. 4. To evaluate association of changes in level of biochemical inflammatory markers with change in liver and splenic stiffness. 5. To evaluate association of baseline liver and splenic stiffness with severity of ACLF by AARC-ACLF score,CLIF-C-ACLF score, MELD-Na and CTP at presentation. 6. To evaluate change in liver and splenic stiffness with change in AARC-ACLF score and CLIF-C-ACLF score. Methodology: Study population All the consecutive patients of ACLF admitted in Hepatology wards will be evaluated for inclusion criteria Study design: Prospective cohort study Study period: 1 year after IEC approval. Sample size: Consecutive patients of ACLF from approval of study to 12 months. 200 patients will be enrolled in our study Intervention: None Monitoring and assessment: All enrolled patients will undergo detailed evaluation by thorough history, clinical examination and relevant laboratory investigations. Patients will be graded as per AARC score grade I (5-7), II (8-10), III (11-15). CBC /NLR, KFT, LFT, PT/INR at baseline and alternate day, till discharge or death/Liver transplantation. TNF alpha, IL-6, CRP, ferritin, lactate at day 1, day 7 and day 14. AARC-ACLF score and CLIF-C-ACLF score at day 1, day 7 and day 14.USG abdomen and hepatic vein, porto-splenic doppler study will be performed in all cases and triple phase CT of abdomen when there will be suspicion of HCC. Fibroscan of liver and spleen at day 1, day 7 and day 14.UGI endoscopy will be performed within 7 days. Initial Liver and Splenic stiffness and follow-up tests (Liver and splenic stiffness, TNF-alpha, IL-6) will be done free of cost. STATISTICAL ANALYSIS: Baseline data will be expressed as a proportion(%), the continuous data will be presented as mean+-SD OR mean ± SD or median ( IQR). To compare between the groups, either, Student's t-test/ Mann Whitney test will be applied, as appropriate. The categorical data will be analysed using χ2test or Fisher's exact test. The change between pre- and post-values will be analysed using paired t-test or McNemar test. Significance defined as 2-tailed p-value of less than 0.05. Survival curves will be represented using Kaplan-Meier method. ITT/ Per protocol analysis will be carried out for final result assessment. The data will be entered in Microsoft excel format and to be analysed using SPSS version 22 (IBM corp Ltd.; Armonk NY, USA). Adverse effects: NA


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date September 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Patients of ACLF as per APASL criteria between 18 to 70 years of age 2. Patient and attendants willing to give informed consent Exclusion Criteria: 1. Age <18 years and > 70 years 2. Survival less than 7 days 3. Cirrhosis with prior decompensation 4. Grade 3 ascites 5. Hepatic encephalopathy grade III &IV 6. HCC/SOL >2cm in liver 7. Patient with congestive heart failure 8. Patient with extrahepatic cholestasis 9. Portal vein thrombosis 10. BMI >30 kg/m2 11. Prior variceal endotherapy or ongoing beta blocker treatment for varices 12. Pregnant and lactating women 13. Patient with cardiac pacemaker 14. Critically ill patients

Study Design


Intervention

Other:
No intervention
No intervention

Locations

Country Name City State
India Institute of Liver & Biliary Sciences New Delhi

Sponsors (1)

Lead Sponsor Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute changes in liver and splenic stiffness on day 7 in patients of ACLF predicts liver transplant free survival at 3 months. 3 months
Secondary Acute changes in liver and splenic stiffness on day 14 in patients of ACLF predicts liver transplant free survival at 3 months 3 months
Secondary Association of baseline and change in liver and splenic stiffness with etiology of ACLF Day 14
Secondary Association of baseline liver and splenic stiffness with severity of ACLF by AARC-ACLF score, at presentation Day 1
Secondary Association of baseline liver and splenic stiffness with severity of ACLF by CLIF-C-ACLF score, at presentation Day 1
Secondary Association of baseline liver and splenic stiffness with severity of ACLF by MELD-Na at presentation Day 1
Secondary Association of baseline liver and splenic stiffness with severity of ACLF by CTP at presentation Day 1
Secondary Association of baseline liver and splenic stiffness with grade of esophageal varices in ACLF patients 1-7 days
Secondary Association of baseline and change in liver and splenic stiffness with pattern of organ failures. Day 14
Secondary Association of changes in level of biochemical inflammatory markers with change in liver and splenic stiffness. Day 14
Secondary Association of change in liver and splenic stiffness with change in AARC-ACLF score. Day 14
Secondary Association of change in liver and splenic stiffness with change in CLIF-C-ACLF score. Day 14
See also
  Status Clinical Trial Phase
Recruiting NCT03754400 - Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial). N/A
Not yet recruiting NCT06066814 - To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.
Completed NCT02573727 - To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure N/A
Completed NCT02583698 - Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices N/A
Not yet recruiting NCT06116305 - Lactate Kinetics as a Predictor of Survival in ACLF With Septic Shock
Completed NCT01074645 - Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure Phase 4
Recruiting NCT05124041 - Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy N/A
Not yet recruiting NCT06340269 - Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF N/A
Recruiting NCT01866072 - Evaluation of Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure N/A
Terminated NCT02788240 - To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase N/A
Not yet recruiting NCT05772585 - Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Withdrawn NCT05131230 - CytoSorb® in Patients With Acute on Chronic Liver Failure
Completed NCT02467348 - Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure. N/A
Not yet recruiting NCT06276907 - An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response N/A
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Completed NCT02307409 - Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis N/A
Completed NCT03065699 - Safety and Performance Trial of DIALIVE Liver Dialysis Device in Acute On Chronic Liver Failure Patients N/A
Recruiting NCT02757170 - Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Phase 4
Recruiting NCT04054037 - A Study of AARC Standards on Diagnosis and Treatment of Patients With HBV-ACLF in China (AARC China Study)
Recruiting NCT05180292 - Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study. N/A